MedPath

Scars After Central Venous Catheters

Phase 3
Conditions
Hypertrophic Scars
Keloids
Interventions
Drug: Betamethason-17-valerate and fusidic acid
Registration Number
NCT01113125
Lead Sponsor
Mette Møller Handrup
Brief Summary

Most children with cancer need a central venous catheter. These catheters are typically placed on the anterior thorax, where the risk of hypertrophic scarring and keloid development is greatly enhanced. A significant part of the children who have survived childhood cancer are troubled by their scars.

Topical glucocorticoid treatment is known to induce a reduction of the collagen in the connective tissue.

The investigators hypothesize that treatment with topical glucocorticoids for one week before and three weeks after removal of a central venous catheter, will reduce the formation of hypertrophic scarring and keloid development in children.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • All children and adolescents who have a central venous catheter removed at the Childrens Department of Oncology at Aarhus University Hospital Skejby in the period from March 2010 to July 2011
Exclusion Criteria
  • Known allergy towards plaster or fusidic acid

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
FucicortBetamethason-17-valerate and fusidic acid-
FucidinFusidic Acid-
Primary Outcome Measures
NameTimeMethod
scars measured by the Vancouver Scar Scale twelve months after central venous catheter removalTwelve months
Secondary Outcome Measures
NameTimeMethod
Judgement of the scar by Patient and observer scar scale after six monthssix months
Judgement of the scar by Patient and observer scar scale after twelve monthstwelve months
scars measured by the Vancouver Scar Scale six months after central venous catheter removalsix months

Trial Locations

Locations (1)

Arhus University Hospital Skejby

🇩🇰

Aarhus, Aarhus N, Denmark

© Copyright 2025. All Rights Reserved by MedPath